Skip to content
Comparison

BPC-157 vs NAD+

BPC-157 and NAD+ are commonly compared for injury repair versus cellular energy support. BPC-157 is usually favored for localized tendon/gut tissue-repair intent, while NAD+ is often preferred for systemic metabolic and mitochondrial support. This head-to-head analysis focuses on mechanism, trial outcomes, dosing context, evidence quality, regulatory status, and practical decision points for safer YMYL decision-making.

4.3(112 ratings)

Quick Answer

For injury repair versus cellular energy support, the better choice depends on your primary endpoint. BPC-157 is stronger when the priority is structural injury-healing goals. NAD+ is stronger when the priority is fatigue/energy resilience and recovery support. Use evidence grade, dose intensity, access constraints, and tolerability profile to match therapy to the patient profile rather than choosing by hype alone.

Head-to-Head Comparison

CriteriaBPC-157NAD+
Primary mechanismCytoprotective peptide with angiogenic and tendon-healing signalingCoenzyme replenishment strategy for mitochondrial and metabolic pathways
Strongest clinical signalStrong preclinical tissue-repair data across tendon, gut, and soft tissueSignals for improved cellular energetics and metabolic resilience
Typical dosing context200-500 mcg once or twice dailyIV, IM, SC, or oral precursor protocols vary widely
AdministrationSubcutaneous/perilesional or oral forms used in practiceClinic infusions/injections or oral support stacks
Evidence quality gradePreclinical-dominant, limited human RCT-quality evidenceModerate mechanistic evidence; heterogeneous clinical outcomes
Regulatory statusNot FDA-approvedNot an FDA-approved disease-specific peptide therapy
Side-effect burdenGenerally well tolerated in reported use; human safety certainty limitedGenerally tolerated; protocol quality and formulation matter
Cost/access contextModerate peptide-market costHigh for infusion-heavy protocols
Best candidate profileLocalized tendon/ligament and gut-focused recovery goalsEnergy/fatigue and metabolic-support strategies
Main limitationHuman efficacy evidence remains early-stageOutcome heterogeneity and protocol standardization gaps
Best use case in this comparisonstructural injury-healing goalsfatigue/energy resilience and recovery support

When to Choose Each

Choose BPC-157

Best for structural injury-healing goals.

Choose NAD+

Best for fatigue/energy resilience and recovery support.

Verdict

If the main goal is structural injury-healing goals, BPC-157 is usually the better first-line choice. If the main goal is fatigue/energy resilience and recovery support, NAD+ is typically the better fit. Reassess outcomes at 8-16 weeks with objective metrics, then adjust only when response, safety, or adherence data justify it. In high-risk populations, physician-guided personalization matters more than any generic ranking.

References

  1. BPC 157 and its effects on the musculoskeletal system — a systematic review (2020) — PubMed
  2. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts (2010) — PubMed
  3. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract (2011) — PubMed
  4. Pentadecapeptide BPC 157 and its effects in the central nervous system (2020) — PubMed

Compare Telehealth Providers

Find the right provider for your peptide therapy needs

Hims & Hers

Most Popular
4.3

Starting at $199/mo

Hims & Hers is a leading telehealth platform offering physician-supervised GLP-1 weight loss programs including compounded semaglutide and tirzepatide. Board-certified providers, async or video consults, and medication shipped to your door.

✓Large, established platform with strong physician network
✓Compounded semaglutide available where branded shortages exist
✓Easy async consult — no video call required
✗Does not offer a wide range of peptides beyond GLP-1s
✗Pricing is on the higher end for GLP-1 programs

Henry Meds

Most Peptides
4.2

Starting at $249/mo

Henry Meds is a telehealth provider specializing in hormone optimization and peptide therapy. Beyond GLP-1 weight loss, Henry Meds offers testosterone replacement therapy, growth hormone peptides, and other advanced hormonal protocols managed by licensed physicians.

✓Broadest peptide therapy menu of any major telehealth provider
✓Growth hormone peptides (sermorelin, ipamorelin, CJC-1295) available
✓Repair peptides including BPC-157 and TB-500
✗Higher starting price due to comprehensive programs
✗More complex onboarding including lab work requirements

Ro Body

Best Value
4.1

Starting at $149/mo

Ro Body is a telehealth weight management program powered by GLP-1 medications. Ro connects patients with licensed providers who prescribe compounded semaglutide or branded GLP-1 therapies depending on eligibility, paired with behavioral coaching.

✓Competitive pricing starting at $149/mo
✓Dedicated health coach included in program
✓Strong clinical protocols with lab-work integration
✗Narrower peptide offering — GLP-1s only
✗Video consult required for initial visit

Calibrate

4.0

Starting at $199/mo

Calibrate is a metabolic health company offering a one-year GLP-1 program built around four pillars: food, sleep, exercise, and emotional health. Calibrate works with insurance to cover medication costs and provides extensive behavioral coaching alongside prescriptions.

✓Insurance navigation support for medication coverage
✓Evidence-based one-year program with structured milestones
✓Four-pillar lifestyle coaching (food, sleep, exercise, emotional health)
✗Annual program commitment required
✗Primarily focused on GLP-1s — no broader peptide therapy

Found

3.9

Starting at $129/mo

Found is a weight management telehealth platform that combines GLP-1 medications with behavioral coaching and a supportive community. Found emphasizes a whole-person approach, pairing pharmacological treatment with lifestyle intervention for sustainable results.

✓One of the more affordable monthly program fees
✓Strong community and peer support features
✓Certified health coaches with regular check-ins
✗Medication billed separately from program fee — total cost can be higher
✗Limited peptide variety beyond standard GLP-1s

Sponsored · We may earn a commission. Learn more · Updated February 2026

Henry MedsMost Peptides

Henry Meds is a telehealth provider specializing in hormone optimization and peptide therapy. Beyond GLP-1 weight loss, Henry Meds offers testosterone replacement therapy, growth hormone peptides, and other advanced hormonal protocols managed by licensed physicians.

From $249/moLearn More →

Sponsored · Affiliate Disclosure

Frequently Asked Questions

Which has stronger evidence for injury repair versus cellular energy support — BPC-157 or NAD+?
BPC-157 is graded as preclinical-dominant, limited human rct-quality evidence evidence in this context, while NAD+ is graded as moderate mechanistic evidence; heterogeneous clinical outcomes. In practice, strength depends on whether you prioritize structural injury-healing goals or fatigue/energy resilience and recovery support. Favor the option with endpoint data closest to your primary goal, and avoid extrapolating beyond studied populations.
Can BPC-157 and NAD+ be combined or sequenced?
Sometimes, but only with clinician oversight. A common framework is to start with one agent, track objective response for 8-16 weeks, then switch or sequence if outcomes plateau or tolerability is poor. Combination protocols may increase both cost and adverse-effect complexity, so they should be justified by clear endpoint-based rationale.
What should be monitored before and during treatment?
Baseline assessment should include diagnosis confirmation, comorbidity risk, and contraindications. During therapy, monitor target outcomes (symptoms, body composition, labs), adverse effects, and adherence burden. For endocrine/metabolic strategies, periodic glucose, lipids, organ function, and indication-specific labs help keep risk proportional to expected benefit.

Explore next